FocusOn Healthcare
  • Women's Health
  • Bone Health
  • Urology
  • Cardiology
  • Gastroenterology
  • Neurology
  • Oncology
  • Specialties:
  • Women's Health
  • Bone Health
  • Urology
  • Cardiology
  • Head Pain
  • Gastroenterology
  • Neurology
  • Oncology

Real-world insights: Neoadjuvant KEYNOTE-522 regimen in triple-negative breast cancer patients with germline BRCA mutations

  • Journal of Clinical Oncology
  • May 2025
Share:
Breast Cancer Awareness Month Peer-Reviewed Articles

Read Full Article

Abstract

Background: Triple-negative breast cancer (TNBC) is the most immunogenic subtype and is highly prevalent among patients (pts) with germline BRCA1/2 mutations (gBRCAm). Regardless of mutation status, the current standard treatment for early-stage TNBC is chemotherapy combined with pembrolizumab, as per the KEYNOTE-522 protocol.

Share

Modal body text goes here.

FocusOn logo
  • About FocusOn
  • Privacy Policy
  • Terms of Use

© 2025 Wolters Kluwer. All right reserved.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our Privacy and Cookie Policy.

|
|

Cookie Policy

Information about our use of cookies

Wolters Kluwer ("we" or "us") wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain what personal information we collect, use and disclose.

Personal information means any data relating to an individual who can be identified, directly or indirectly, based on that information. This may include information such as names, contact details, (online) identification data, online identifiers, or other characteristics specific to that individual.

Read More